journal article·2022-12

Drug delivery in transarterial chemoembolization of hepatocellular carcinoma: Ex vivo evaluation using transparent tissue imaging

Sera Hong, Won Seok Choi, Baskaran Purushothaman, Jaemoon Koh, Hyo-Cheol Kim, Jin Wook Chung, Joon Myong Song, Jin Woo Choi

Acta Biomaterialia· Volume 154
Publisher page

Abstract

In this study, we elucidated for the first time the role of anti-cancer drugs in transarterial chemoembolization (TACE) via direct visualization of the spatial distribution of drugs with respect to blood vessels in intact transparent hepatocellular carcinoma (HCC) tissues. To date, precise estimation of drug penetration into tumors using thin 3D tissue sections has been challenging. This study utilized the tissue optical clearing technique to resolve the lack of tissue clarity, thereby enabling deep tissue imaging for the quantitative assessment of drug delivery following TACE. We compared the drug delivery effect, time-dependent embolic effect, and immunogenic response following conventional TACE (cTACE), drug-eluting embolic TACE (DEE-TACE), and transarterial embolization (TAE) in a rat model of HCC. After each treatment, three-dimensional drug delivery was quantitatively evaluated via the transparent liver tumor imaging, and time-dependent tumor necrosis was analyzed by serial tumor harvesting and histological staining. The results showed that chemotherapeutic agents travel only short distances after cTACE (∼80µm) and DEE-TACE (∼110µm), whereas necrosis occurs extensively within 24 h of treatment (85.3-97.2% of tumor cells). In addition, the percentages of CD4 and IL-17+ CD4 T cells increased significantly following treatment; however, drug-loading did not appear to affect the immune response following TACE. In conclusion, transarterially delivered chemotherapeutic agents appeared to exert a limited role, owing to the rapid and overwhelming effect of embolization. STATEMENT OF SIGNIFICANCE: TACE has been widely used for the treatment of HCC, especially for unresectable intermediate and advanced HCCs. Drug use in TACE is expected to provide patients with synergistic therapeutic benefits with the effect of embolic agents; however, the role of chemotherapeutic agents in TACE remains controversial. This study quantitatively verified that chemotherapeutic agents travel only short distances after TACE, while necrosis occurs extensively within 24h, and drug loading does not significantly affect immune responses following TACE. Three-dimensional imaging of intact transparent HCC can contribute to a better understanding of drug delivery mechanisms associated with TACE and also reveal that drug use in TACE may need to be reconsidered and limited to situations when embolization is expected to be insufficient.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hepatocellular Carcinoma Treatment and Prognosis · Cancer, Hypoxia, and Metabolism · Mathematical Biology Tumor Growth

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Hepatocellular carcinoma: old friends and new tricks10.1038/s12276-020-00527-1 ↗
2. Hepatocellular Carcinoma10.1056/NEJMra1713263 ↗
3. AASLD guidelines for the treatment of hepatocellular carcinoma10.1002/hep.29086 ↗
4. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma10.1016/j.jhep.2018.03.019 ↗
5. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies10.1007/s00270-006-0062-3 ↗
6. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors
7. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization10.1097/01.RVI.0000195323.46152.B3 ↗
8. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics10.1016/j.jhep.2006.10.020 ↗
9. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads
10. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study10.1007/s00270-009-9711-7 ↗
11. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial10.2214/AJR.10.4379 ↗
12. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma10.1038/bjc.2014.199 ↗
13. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone10.1200/JCO.2015.64.0821 ↗
14. Chemoembolization or bland embolization for hepatocellular carcinoma: the question is still unanswered10.1200/JCO.2016.67.2915 ↗
15. Delusional beliefs and hepatocellular carcinoma10.1200/JCO.2016.67.2337 ↗
16. Transarterial embolization with or without chemotherapy: what should be the indication for patients with hepatocellular carcinoma?10.1200/JCO.2016.68.4902 ↗
17. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer10.1016/j.actbio.2021.05.031 ↗
18. Structural and molecular interrogation of intact biological systems10.1038/nature12107 ↗
19. Advances and perspectives in tissue clearing using CLARITY10.1016/j.jchemneu.2017.07.005 ↗
20. A review of the optical properties of biological tissues10.1109/3.64354 ↗
21. Diffusion in brain extracellular space10.1152/physrev.00027.2007 ↗
22. Transparent tumor microenvironment: Are liposomal nanoparticles sufficient for drug delivery to hypoxic regions and clonogenic cells?
23. Doxorubicin-loaded poly(lactic-co-glycolic acid) microspheres prepared using the solid-in-oil-in-water method for the transarterial chemoembolization of a liver tumor10.1016/j.colsurfb.2015.05.037 ↗
24. Modified rat hepatocellular carcinoma models overexpressing vascular endothelial growth factor10.1016/j.jvir.2018.07.005 ↗
25. Spontaneous tumor regression in a syngeneic rat model of liver cancer: implications for survival studies10.1016/j.jvir.2012.08.025 ↗
26. Comparison of tumor vascularity and hemodynamics in three rat hepatoma models10.1007/s00261-015-0591-9 ↗
27. Sprague-Dawley rats bearing McA-RH7777 cells for study of hepatoma and transarterial chemoembolization
28. Hepatic arterial bland embolization increases Th17 cell infiltration in a syngeneic rat model of hepatocellular carcinoma10.1007/s00270-019-02343-1 ↗
29. Sample size calculation in animal studies using resource equation approach10.21315/mjms2017.24.5.11 ↗
30. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model10.1016/j.jvir.2009.10.026 ↗
31. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma10.1016/j.jvir.2009.10.038 ↗
32. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma10.1007/s00270-012-0352-x ↗
33. Single- versus triple-drug chemoembolization for hepatocellular carcinoma: comparing outcomes by toxicity, imaging response, and survival10.1016/j.jvir.2016.01.135 ↗
34. Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug tace using doxorubicin-eluting beads: long-term survival in 313 patients10.2214/AJR.17.18219 ↗
35. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery10.1016/j.jconrel.2010.08.027 ↗
36. Progress and challenges towards targeted delivery of cancer therapeutics10.1038/s41467-018-03705-y ↗
37. Tumor vasculature-targeting nanomedicines10.1016/j.actbio.2021.07.015 ↗
38. Physiological fluid interfaces: Functional microenvironments, drug delivery targets, and first line of defense10.1016/j.actbio.2021.05.051 ↗
39. Openings between defective endothelial cells explain tumor vessel leakiness10.1016/S0002-9440(10)65006-7 ↗
40. Cancer cells compress intratumour vessels10.1038/427695a ↗
41. High interstitial fluid pressure - an obstacle in cancer therapy10.1038/nrc1456 ↗
42. Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor10.1038/s41598-017-00709-4 ↗
43. Hyaluronic acid/doxorubicin nanoassembly-releasing microspheres for the transarterial chemoembolization of a liver tumor10.1080/10717544.2018.1480673 ↗
44. Effect of transcatheter intraarterial therapies on the distribution of Doxorubicin in liver cancer in a rabbit model10.1371/journal.pone.0076388 ↗
45. Improved ADM penetration distance and therapeutic efficiency in a rabbit VX2 liver cancer model by relaxin infusion combined with transcatheter chemoembolization through hepatic artery10.2147/CMAR.S223993 ↗
46. Anthracyclines potentiate anti-tumor immunity: a new opportunity for chemoimmunotherapy10.1016/j.canlet.2015.10.002 ↗
47. The secret ally: immunostimulation by anticancer drugs10.1038/nrd3626 ↗